Pharmala Biotech Holdings Inc
Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.
Pharmala Biotech Holdings Inc (MDXXF) - Total Assets
Latest total assets as of November 2025: $3.40 Million USD
Based on the latest financial reports, Pharmala Biotech Holdings Inc (MDXXF) holds total assets worth $3.40 Million USD as of November 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pharmala Biotech Holdings Inc - Total Assets Trend (2021–2025)
This chart illustrates how Pharmala Biotech Holdings Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Pharmala Biotech Holdings Inc - Asset Composition Analysis
Current Asset Composition (August 2025)
Pharmala Biotech Holdings Inc's total assets of $3.40 Million consist of 48.2% current assets and 51.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.2% |
| Accounts Receivable | $78.13K | 2.3% |
| Inventory | $369.71K | 10.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.77 Million | 51.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Pharmala Biotech Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pharmala Biotech Holdings Inc's current assets represent 48.2% of total assets in 2025, a decrease from 90.6% in 2021.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2025, down from 88.5% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 51.8% of total assets.
Pharmala Biotech Holdings Inc Competitors by Total Assets
Key competitors of Pharmala Biotech Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Pharmala Biotech Holdings Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Pharmala Biotech Holdings Inc generates 0.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Pharmala Biotech Holdings Inc is currently not profitable relative to its asset base.
Pharmala Biotech Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.60 | 1.07 | 1.34 |
| Quick Ratio | 1.25 | 0.59 | 1.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $617.56K | $ 53.96K | $ 259.44K |
Pharmala Biotech Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Pharmala Biotech Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.40 |
| Latest Market Cap to Assets Ratio | 2.60 |
| Asset Growth Rate (YoY) | 18.0% |
| Total Assets | $3.42 Million |
| Market Capitalization | $8.89 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Pharmala Biotech Holdings Inc's assets at a significant premium ( 2.60x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Pharmala Biotech Holdings Inc's assets grew by 18.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pharmala Biotech Holdings Inc (2021–2025)
The table below shows the annual total assets of Pharmala Biotech Holdings Inc from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-08-31 | $3.42 Million | +18.00% |
| 2024-08-31 | $2.90 Million | +20.13% |
| 2023-08-31 | $2.41 Million | +3.54% |
| 2022-08-31 | $2.33 Million | -16.60% |
| 2021-08-31 | $2.79 Million | -- |